ECYT

Why Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today

By Karl Utermohlen, InvestorPlace Writer
Endocyte (ECYT) shares soared nearly 50% early Tuesday as the company unveiled the results of a new treatment for a type of prostate cancer.

16 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

26 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The ratings of 26 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

14 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
This week, the ratings of 14 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

16 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of 16 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

12 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Cancer-Fighting Stocks Making Waves in the Markets

By Josh Enomoto, InvestorPlace Contributor
After tripping up early in the year, cancer-fighting stocks JUNO, ECYT and SGEN are setting the stage for a comeback rally.

3 Pharmaceutical Stocks to Buy Now

By Portfolio Grader
The grades of three Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").